Evidence map›Paper›PMID 27356882›Full record

ArticleScientific reports2016

Human Organotypic Cultured Cardiac Slices: New Platform For High Throughput Preclinical Human Trials.

C Kang, Y Qiao, G Li, K Baechle, P Camelliti, S Rentschler, I R Efimov

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 111 citations in OpenAlex.

  1. A Beginner's Guide to Cardiac Optical Mapping.Cardiovascular engineering and technology · 2026
    Review
  2. Optogenetic tachypacing facilitates burst-induced arrhythmia in stem cell-derived human atrial engineered heart tissue.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. RNAi-mediated p38δ silencing mitigates anthracycline cardiotoxicity in female mice.American journal of physiology. Heart and circulatory physiology · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Living myocardial slices as a model for testing cardiac pro-reparative gene therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  13. Generation and applications of cardiac spheroids.npj biomedical innovations · 2025
    Review
  14. Review
  15. Dressed in Collagen: 2D and 3D Cardiac Fibrosis Models.International journal of molecular sciences · 2025
    Review
  16. Article
  17. Review
  18. Non-Coding RNA-Targeted Therapy: A State-of-the-Art Review.International journal of molecular sciences · 2024
    Review
  19. Synchronous force and CaCommunications biology · 2024
    Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

C KangWashington University in St. Louis, St. Louis MO, USA.
Y QiaoWashington University in St. Louis, St. Louis MO, USA.
G LiWashington University in St. Louis, St. Louis MO, USA.
K BaechleWashington University in St. Louis, St. Louis MO, USA.
P CamellitiUniversity of Surrey, Guildford, UK.
S RentschlerWashington University in St. Louis, St. Louis MO, USA.
I R EfimovWashington University in St. Louis, St. Louis MO, USA.
Washington University in St. Louis · USElectrophysiology and Heart Modeling Institute · FRUniversity of Surrey · GB

Funding

Exploration of Arrhythmogenic Triggers and Substrates in Heart FailureR01HL126802 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI EFIMOV, IGOR R, GORELIK, JULIA · 2016 to 2019
$2.8M
ARRHYTHMOGENIC REMODELING IN HUMAN HEART FAILURER01HL114395 · NHLBI · WASHINGTON UNIVERSITY · PI EFIMOV, IGOR R · 2012 to 2015
$2.1M
NHLBI NIH HHS R01 HL114395NHLBI NIH HHS R01 HL126802
6 · The paper itself

Abstract

Translation of novel therapies from bench to bedside is hampered by profound disparities between animal and human genetics and physiology. The ability to test for efficacy and cardiotoxicity in a clinically relevant human model system would enable more rapid therapy development. We have developed a preclinical platform for validation of new therapies in human heart tissue using organotypic slices isolated from donor and end-stage failing hearts. A major advantage of the slices when compared with human iPS-derived cardiomyocytes is that native tissue architecture and extracellular matrix are preserved, thereby allowing investigation of multi-cellular physiology in normal or diseased myocardium. To validate this model, we used optical mapping of transmembrane potential and calcium transients. We found that normal human electrophysiology is preserved in slice preparations when compared with intact hearts, including slices obtained from the region of the sinus node. Physiology is maintained in slices during culture, enabling testing the acute and chronic effects of pharmacological, gene, cell, optogenetic, device, and other therapies. This methodology offers a powerful high-throughput platform for assessing the physiological response of the human heart to disease and novel putative therapies.

Indexed as

CalciumCells, CulturedElectrodesGreen Fluorescent ProteinsHeartHeart VentriclesHigh-Throughput Screening AssaysHumansImmunohistochemistryInduced Pluripotent Stem CellsIn Vitro TechniquesIsoproterenolMembrane PotentialsMyocardiumMyocytes, CardiacVentricular FunctionCalciumenhanced green fluorescent proteinGreen Fluorescent ProteinsIsoproterenol

Identifiers

PMID27356882
PMCPMC4928074
OpenAlexW2472601291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.